1. J. G. Massicot, R. J. Soberman, N. R. Ackerman, D. Heavey, L. J. Roberts, and K. F. Austen, Workshop: Potential Therapeutic Uses of Leukotriene Generation and Function, Prostaglandins 32: 481 (1986).
2. A. Blackham, R. J. Griffiths, C. Hallam, J. Mann, P. D. Mitchell, A. A. Norris, and W. T. Simpson, FPL 62064, a Topically Active 5-Lipoxygenase/Cyclooxygenase Inhibitor, Agents and Actions 30: 432 (1990)
3. H. Tsunoda, S. Katayama, Y. Sakuma, S. Tanaka, K. Tsukidate, S. Abe, I. Yamatsu, and K. Katayama, Effect of a Novel 5-Lipoxygenase Inhibitor, E6080 on Bronchospasm, Airway Cellular Infiltration and Leukotriene Production in Guinea Pigs, Prostaglandins Leukotrienes Essential Fatty Acids 42: 51 (1991).
4. E. Israel, R. Dermarkarian, M. Rosenberg, R. Sperling, G. Taylor, P. Rubin, and J. M. Drazen, The Effects of a 5-Lipoxygenase Inhibitor on Asthma Induced by Cold, Dry Air, N. Engl. J. Med. 323:1740 (1990)
5. R. A. Hahn, B. R. MacDonald, P. J. Simpson, L. Wang, R. D. Towner, P. P. K. Ho, R. M. Goodwin, A. P. Breau, T. Suarez, and E. D ‘Mihelich Characterization of LY233569 on 5-Lipoxygenase and Reperfusion Injury of Ischemic Myocardium, J. Pharmacol. Exp. Ther. 256:94 (1990)